



End Session

- Home
- Companies
- Funds
- ETFs
- Markets
- Articles & Videos
- Portfolio
- Help & Education
- Newsletters
- Enter a Ticker or Name

## AbbVie Inc ABBV |

PDF Report

- Quote**
- Chart
- Stock Analysis
- Performance
- Key Ratios
- Financials
- Valuation
- Insiders
- Shareholders
- Transcripts
- Filings
- Bonds
- Options

- Overview**
- Company Profile
- Industry Peers

<b>Last Price</b>	<b>Day Change</b>	<b>Open Price</b>	<b>Day Range</b>	<b>52-Week Range</b>	<b>Yield</b>	<b>Market Cap</b>
\$95.12	-0.31   -0.32%	\$ 95.37	94.04-95.42	58.60-98.26	2.68%	151.5 bil
<b>After Hours</b> : 94.92 -0.20   -0.21%		<b>Volume</b>	<b>Avg Vol.</b>	<b>Forward P/E</b>	<b>Price/Book</b>	<b>Price/Sales</b>
As of Mon 11/13/2017 5:05 PM EST   USD		4.0 mil	6.8 mil	14.0	22.8	5.6
					<b>Price/Cash Flow</b>	17.2

### Stock Price ABBV More...



### Morningstar's Take ABBV More...

While AbbVie holds a strong portfolio of marketed and pipeline drugs, the increasing competition to the company's key drug Humira should slow the growth for the company. At over 50%...

[Read full Analyst Report](#)

<b>Fair Value Estimate</b> \$ 85.00	<b>Consider Buying</b> \$ 59.50	<b>Consider Selling</b> \$ 114.75
<b>Fair Value Uncertainty</b> Medium	<b>Economic Moat</b> Narrow	<b>Stewardship</b> Standard
<b>Growth</b>	<b>Profitability</b>	<b>Morningstar Credit Rating*</b>

### Company Profile ABBV More...

#### What Does This Company Do?

AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures

### Dividends ABBV More...

<b>Declared Date</b>	09/08/2017
<b>Ex-Dividend Date</b>	10/12/2017
<b>Latest Indicated Dividend Amount</b>	0.6400
<b>Yield</b>	2.68%
<b>Projected Yield</b>	2.98%

#### Recent Dividends

Date	Type	Amount
10/12/2017	Cash Dividends	0.6400
07/12/2017	Cash Dividends	0.6400
04/11/2017	Cash Dividends	0.6400
01/11/2017	Cash Dividends	0.6400

#### Purchase Options

<b>Direct Investment</b>	Yes
<b>Dividend Reinvestment Plan</b>	Yes

### Competitors ABBV More...

Name	Price	% Chg	TTM Sales \$ mil
<b>AbbVie Inc</b>	<b>\$95.12</b>	<b>-0.32</b>	<b>27,273</b>
Johnson & Johnson	\$139.76	0.14	74,361
Pfizer Inc	\$35.30	0.34	52,471
Roche Holding AG ADR	\$28.62	-0.24	52,175
Roche Holding AG Dividend Right Cert.	\$228.05	0.11	52,175
Roche Holding AG	\$230.00	-0.38	52,175

### Ownership ABBV More ...

		Fund Owners		Insiders	
Name	% Shares Held	% Total Assets	Star Rating		
VA CollegeAmerica Invmt Co of Amer 529E	3.63	5.82	★★★		
Vanguard Total Stock Mkt Idx	2.37	0.54			
VA CollegeAmerica Cap Inc Bldr 529E	1.97	2.66	★★		
VA CollegeAmerica Cap World G/I 529E	1.81	2.89	★★★★		

and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

[Visit Company Website](#)

<b>Sector</b> Healthcare	<b>Industry</b> Drug Manufacturers - Major	<b>Stock Type</b> Aggressive Growth
<b>Employees</b> 29,000	<b>Fiscal Year Ends</b> 2017-12-31	<b>Stock Style</b> Large Growth

### Key Stats ABBV

[More...](#)

	Stock	Ind Avg	Relative to Industry
Price/Earnings TTM	23.2	24.9	
Price/Book	22.8	4.3	
Price/Sales TTM	5.6	4.0	
Rev Growth (3 Yr Avg)	10.9	-1.6	
Net Income Growth (3 Yr Avg)	13.0	-9.6	
Operating Margin % TTM	37.2	21.2	
Net Margin % TTM	24.3	16.9	
ROA TTM	9.8	6.9	
ROE TTM	100.6	17.9	
Debt/Equity	5.1	0.6	
			-                      Avg                      +

### Financials ABBV

[More...](#)

	2016-12	2015-12	Annual 2014-12	2017-09	Quarterly 2016-09
<b>Income Statement</b>					
Revenue	25,638	22,859	19,960	6,995	6,432
Operating Income	9,384	7,537	3,411	2,705	2,361
Net Income	5,953	5,144	1,774	1,631	1,598
Earnings Per Share	3.63	3.13	1.10	1.01	0.97
Diluted Average Shares	1,631	1,637	1,610	1,603	1,640
<b>Balance Sheet</b>					
Current Assets	16,187	16,314	16,088	18,930	16,290
Non Current Assets	49,912	36,736	11,459	49,910	50,336
Total Assets	66,099	53,050	27,547	68,840	66,626
Current Liabilities	9,781	10,894	11,400	13,033	9,103
Total Liabilities	61,463	49,105	25,805	62,153	60,157
Stockholders' Equity	4,636	3,945	1,742	6,687	6,469
<b>Cash Flow</b>					
Cash From Operations	7,041	7,535	3,549	3,271	1,454
Capital Expenditures	-479	-532	-612	-126	-113
Free Cash Flow	6,562	7,003	2,937	3,145	1,341

In millions except "EPS". Currency in USD.

S&P 500 index data: S&P 500 Copyright © 2017

All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS BZX Exchange when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright 2017 Morningstar, Inc.

\*Morningstar Credit Ratings, LLC is a credit rating agency registered with the Securities and Exchange Commission as a nationally recognized statistical rating organizations ("NRSRO"). Under its NRSRO registration, Morningstar Credit Ratings issues credit ratings on financial institutions (e.g., banks), corporate issuers and asset-backed securities. While Morningstar Credit Ratings issues credit ratings on insurance companies, those ratings are not issued under its NRSRO registration. All Morningstar credit ratings and related analysis contained herein are solely statements of opinion and not statements of fact or recommendations to purchase, hold, or sell any securities or make any other investment decisions. Morningstar credit ratings and related analysis should not be considered without an understanding and review of our methodologies, disclaimers, disclosures and other important information found at <http://www.morningstarcreditratings.com>.

Vanguard 500 Index Inv 1.61 0.65 ★★★★★

### Wall St. Recommendations ABBV

[More...](#)

Current	4.0			
Total Analysts : 6		5.0 Buy	3.0 Hold	1.0 Sell

### Market Data ABBV

Beta	1.42
Below 52-Week High	-3.20%
50-Day Moving Average	89.84
200-Day Moving Average	73.26

### Short Interest ABBV

Shares Outstanding	1,596.43 Mil
Float	1,417.28 Mil
Shares Short (as of 10/31/2017)	12.64 Mil
Short % of Float	0.89%
Short Ratio	1.99
Shares Short Chg. (from 10/13/2017)	-11.06%

### Filings ABBV

[More ...](#)

Financials	Announcements
Ownership	Proxy
Registration	Insider Activities

**Contact us.** Please read our User's Agreement and Troubleshooting documents.  
©2017 Morningstar, Inc. All rights reserved.